J&J Risperdal “Not Approvable” For Autism, Alzheimer’s Psychosis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson is considering how to proceed with Risperdalafter two supplemental applications for new indications for the atypical antipsychotic have been deemed "not approvable" by FDA